<p>Cassava Sciences（SAVA -2.61%）的股票在周一上午 11:05 时下跌了 5.3%，此前在早盘时曾下跌了高达 19%。这一下跌是在上周五对 Cassava 前顾问王浩炎（Hoau-Yan Wang）提起联邦诉讼之后发生的。</p>
<p>王被指控涉嫌与提交给美国国家卫生研究院（NIH）用于 Cassava 实验药物 simufilam 的资助申请有关的欺诈行为。这些资助导致 NIH 在 2017 年至 2021 年间向王和 Cassava 发放了约 1600 万美元的奖励。</p>
<h2>这对 Cassava Sciences 意味着什么？</h2>
<p>Cassava 透露一些政府机构已要求提供信息和文件。公司配合了这些调查。目前 Cassava 尚未被指控任何不当行为，尽管生物科技公司在最近的 10-K 申报中承认，“我们无法预测这些正在进行的事务的结果或影响，包括政府机构是否会对我们或他人采取执法行动。”</p>
<p>在关于王被起诉的公开声明中，Cassava 没有透露是否与政府机构有进一步联系。然而，公司在声明中强调，王和他之前工作过的医学院 “并未参与公司的 simufilam 第三阶段临床试验。”</p>
<h2>Cassava Sciences 股票是一个坏消息的买点吗？</h2>
<p>我认为投资者最好在观望 Cassava Sciences 方面。即使不考虑王最近被起诉所带来的不确定性，仍有许多其他生物科技股票提供更好的风险回报比。</p>

SAVA

<p>股份草莓科学（SAVA -2.61%）下跌了 5.3%，原因是前顾问王浩言因与拨款申请相关的欺诈行为被起诉。该公司正在配合政府调查，但结果和影响尚不确定。鉴于生物科技领域存在不确定性和更好的选择，投资者被建议保持观望态度</p>

<p>Shares of <strong>Cassava Sciences</strong>(SAVA -2.61%) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava.</p>
<div class="lb-trans"><p>Cassava Sciences（SAVA -2.61%）的股票在周一上午 11:05 时下跌了 5.3%，此前在早盘时曾下跌了高达 19%。这一下跌是在上周五对 Cassava 前顾问王浩炎（Hoau-Yan Wang）提起联邦诉讼之后发生的。</p>
</div><p>Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam. These grants led to awards of roughly $16 million from the NIH between 2017 and 2021 to Wang and Cassava.</p>
<div class="lb-trans"><p>王被指控涉嫌与提交给美国国家卫生研究院（NIH）用于 Cassava 实验药物 simufilam 的资助申请有关的欺诈行为。这些资助导致 NIH 在 2017 年至 2021 年间向王和 Cassava 发放了约 1600 万美元的奖励。</p>
</div><h2>What does this mean for Cassava Sciences?</h2>
<div class="lb-trans"><h2>这对 Cassava Sciences 意味着什么？</h2>
</div><p>Cassava has revealed that some government agencies have asked for information and documents. The company cooperated with these inquiries. Cassava has not been charged with any misconduct at this point, although the biotech acknowledged in its more recent 10-K filing, &#34;We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against us or others.&#34;</p>
<div class="lb-trans"><p>Cassava 透露一些政府机构已要求提供信息和文件。公司配合了这些调查。目前 Cassava 尚未被指控任何不当行为，尽管生物科技公司在最近的 10-K 申报中承认，“我们无法预测这些正在进行的事务的结果或影响，包括政府机构是否会对我们或他人采取执法行动。”</p>
</div><p>In a public statement about Wang's indictment, Cassava didn't disclose if there had been further contact with government agencies. However, the company emphasized in this statement that Wang and the medical school where he previously worked &#34;have had no involvement in the Company's Phase 3 clinical trials of simufilam.&#34;</p>
<div class="lb-trans"><p>在关于王被起诉的公开声明中，Cassava 没有透露是否与政府机构有进一步联系。然而，公司在声明中强调，王和他之前工作过的医学院 “并未参与公司的 simufilam 第三阶段临床试验。”</p>
</div><h2>Is Cassava Sciences stock a bad-news buy?</h2>
<div class="lb-trans"><h2>Cassava Sciences 股票是一个坏消息的买点吗？</h2>
</div><p>I think investors are better off remaining on the sidelines with regard to Cassava Sciences. Even without the uncertainty associated with Wang's recent indictment, there are plenty of other biotech stocks that offer better risk-reward propositions.</p>
<div class="lb-trans"><p>我认为投资者最好在观望 Cassava Sciences 方面。即使不考虑王最近被起诉所带来的不确定性，仍有许多其他生物科技股票提供更好的风险回报比。</p>
</div>

为什么 Cassava Sciences 的股票今天下跌